Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Publisher： Bentham Science Publishers

E-ISSN： 1873-4316|7|5|339-342

ISSN： 1389-2010

Source： Current Pharmaceutical Biotechnology, Vol.7, Iss.5, 2006-10, pp. : 339-342

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma

By  

Current Cancer Drug Targets, Vol. 17, Iss. 9, 2017-10 ,pp. : 846-857

Bentham Science Publishers

Access to resources Recommend Favorite

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Schafer Peter H  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1541-1542

Informa Healthcare

Access to resources Recommend Favorite

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Vallet Sonia   Witzens-Harig Mathias   Jaeger Dirk   Podar Klaus  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 4, 2012-03 ,pp. : 473-494

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 3, 2003-09 ,pp. : 181-186

Bentham Science Publishers

Access to resources Recommend Favorite

Lenalidomide for Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite